Read our latest updates & insights

Pearce IP New Zealand. A practice with IP in its DNA. In less than two years, Pearce IP’s New Zealand practice has gone from new arrival to recognised player across the region’s leading independent IP rankings and directories. New to New Zealand. Well Established in IP. Pearce IP’s New Zealand practice may be recent, but its expertise isn’t.  

Recent reforms to streamline New Zealand’s medicines approval process may have inadvertently undermined its compliance with an international trade agreement, the CPTPP. From July 2026, New Zealand has implemented a new, fast-track pathway for the approval of pharmaceuticals under sections 22A to 22F of the Medicines Act 1981.

Choosing a new brand can be an exciting part of launching a product, service or business. Once the preferred name has gained internal support, however, commercial momentum can build quickly: domains are secured, packaging is commissioned, regulatory documentation is prepared and marketing plans begin to take shape.

Justice Rofe of the Federal Court of Australia has delivered another decision in the long-running dispute between Kutti Bay Investments Pty Ltd (formerly Jusand Nominees Pty Ltd) and Rattlejack Innovations Pty Ltd. Justice Rofe held that Kutti Bay’s application to amend three standard patents constituted an abuse of process, as it sought to overcome earlier Court decisions in the dispute.

Australia. Preliminary Discovery. A New Frontier. Generics Are Now Using Preliminary Discovery in AU to Determine Whether to Mount Validity Challenges. Preliminary discovery applications are becoming increasingly common in the context of patent disputes in Australia.

The Full Court of the Federal Court of Australia (Justices Beach, Jackson and Jackman) has issued a further, and what appears to be the final, decision in the long-running litigation between Nalco Company (Nalco) and Cytec Industries Inc (Cytec). 

In a significant PBS pricing decision, Justice Downes held that the PBS listing of Alphapharm’s generic Descovy® would also trigger statutory price reductions for several of Gilead’s related combination therapies, including Odefsey®, Biktarvy® and Genvoya®, under s 99ACC of the National Health Act.